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 Introduction 
 Sweet’s syndrome (SS), or acute febrile 
neutrophilic dermatosis, belongs to the 
group of the so-called neutrophilic derma-
toses and was first described in 1964 by 
Robert Douglas Sweet  [1] . The cutaneous 
lesions of SS typically appear as tender, red 
or purple-red papules or nodules. They 
most frequently occur on the upper ex-
tremities, face and neck  [2] . Less common-
ly SS can present as a pustular dermatosis 
 [3] . Affected patients may appear dramat-
ically ill. Fever and leukocytosis usually
accompany the skin eruption. Several clin-
ical conditions have been linked to SS. A 
probable association between the occur-
rence of the following conditions and the 
development of SS is considered likely: 
cancer (hematologic malignancies and sol-
id tumors), infections (most commonly of 
the upper respiratory tract and the gastro-
intestinal tract), inflammatory bowel dis-
ease (IBD) (includes Crohn’s disease and 
ulcerative colitis), medications (granulo-
cyte colony-stimulating factor [G-CSF] as 
the most commonly reported medication), 
and pregnancy  [2] .
 Various medications have been report-
ed to induce SS, including G-CSF, anti-
biotics, retinoids, antiepileptics and anti-
hypertensives. More recently azathioprine 
 Key Words 
 Azathioprine · Inflammatory bowel
disease · Neutrophilic dermatosis · Sweet’s 
syndrome · Interleukin-1β 
 Abstract 
 Sweet’s syndrome (SS) is a dermatosis with 
systemic symptoms characterized by tender, 
red nodules or papules, occasionally covered 
with vesicles, pustules or bullae, usually af-
fecting the upper limbs, face and neck. SS is 
frequently observed in patients with leuke-
mia or connective tissue diseases, while it is 
rather seldom in patients with inflammatory 
bowel disease. The exact pathogenesis of SS 
is only partially understood. We report the 
case of a 50-year-old patient with indetermi-
nate colitis, presenting with a febrile diffuse 
papulopustular and necrotizing skin erup-
tion that healed with significant scarring and 
appeared 14 days after onset of treatment 
with azathioprine. Histological examination 
revealed the presence of features typical of 
SS, gene expression analysis very high levels 
of interleukin-1β (IL-1β) mRNA in lesional 
skin, and immunohistochemistry high levels 
of IL-1β at the protein level. SS associated 
with azathioprine is being increasingly re-
ported and is reviewed herein. 
 © 2015 S. Karger AG, Basel 
 Received: October 6, 2014 
 Accepted after revision: January 2, 2015 
 Published online: March 14, 2015 
 Laurence Imhof, MD 
 Department of Dermatology, University Hospital 
 Gloriastrasse 31 
 CH–8091 Zurich (Switzerland) 
 E-Mail laurence.imhof   @   usz.ch 
 © 2015 S. Karger AG, Basel
1018–8665/15/2304–0293$39.50/0 
 www.karger.com/drm 
(AZA), the nitroimidazole of 6-mercapto-
purine, which is widely used as a corticoste-
roid-sparing agent in a variety of autoim-
mune inflammatory diseases, has been in-
creasingly reported as a potential cause of 
SS  [4–14] . Here we report a severe case of 
SS associated with AZA therapy, review the 
literature concerning similar cases report-
ed to date and analyze the expression of the 
proinflammatory cytokine interleukin-1β 
(IL-1β) in our patient’s skin lesions.
 Case Description 
 A 50-year-old male smoker was emer-
gently referred to our department for an 
impressive febrile diffuse pustular and nec-
rotizing skin eruption. He had a back-
ground history of a IBD, namely indeter-
minate colitis affecting the sigmoid colon 
that had first been diagnosed 5 months pre-
viously. Oral sulfasalazine therapy had 
been ineffective. Approximately 5 weeks 
prior to presentation, he had experienced
a flare of his colitis managed with an oral 
medication of 50 mg prednisone daily. 14 
days prior to presentation, AZA had been 
introduced at a dose of 50 mg once daily.
 The patient’s current illness began 
about 4 days prior to his transfer to our 
department. He initially developed a mac-
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ulopapular rash predominantly on the 
trunk, accompanied by high fever and
fatigue. In the following days he devel-
oped a painful cutaneous eruption that was 
most marked over the upper back, shoul-
ders, neck and face. This was accompanied 
by loose, partially bloody diarrhea with 
more than twenty bowel movements per 
day. There were no relevant symptoms 
pertaining to other organ systems. Upon 
arrival he was febrile (39.6   °   C), tachycar-
dic (129 beats/min) and had a blood pres-
sure of 116/84 mm Hg. Examination of
the patient’s skin revealed a florid erup-
tion consisting of scattered well-delimited 
nummular erythematous papulopustular 
lesions 2–10 mm in diameter, many of 
which were depressed in the center ( fig. 1 ). 
Fresh lesions were infiltrated erythematous 
plaques with a central pustule; older lesions 
were infiltrated erythematous plaques with 
a brown-colored central crust. The cutane-
ous eruption was mostly confined to the 
upper torso, face and neck, but the mucosa 
was also affected, with aphthous lesions 
5–10 mm in diameter and a fibrinous base 
( fig. 2 ).
 Laboratory results showed a strongly el-
evated white cell count with pronounced 
neutrophilia and markedly raised C-reac-
tive protein ( table  1 ). Swabs were taken 
from the pustular skin lesions for culture, 
and two sets of blood cultures were collect-
ed. An incisional skin biopsy was taken 
from a pustular plaque on the right upper 
back for histopathology.
 Pending the results of the above inves-
tigations, a provisional diagnosis of neu-
trophilic dermatosis (most closely resem-
bling SS) was made, and the patient’s daily 
prednisone 50 mg dose was substituted by 
intravenous hydrocortisone 400 mg daily. 
The condition was considered to be likely 
associated with the patient’s underlying 
colitis, and since AZA-induced SS had 
been reported in a handful of previously 
published cases, therapy with AZA was in-
terrupted. The patient responded well to 
intravenous steroids with flattening of his 
skin lesions, disappearance of the pustules 
and appearance of crusts covering the le-
sions. Simultaneously his body tempera-
ture normalized. Histopathological exami-
nation of the skin biopsy taken at onset 
( fig. 3 ) revealed marked superficial edema 
with florid neutrophilic infiltration in the 
whole dermal thickness, consistent with SS 
syndrome. Cultures taken prior to antibi-
otic therapy from blood and skin swabs 
were all sterile. Complete healing of skin 
lesions with residual hypopigmented scars 
occurred within 3 weeks. Given the pa-
tient’s active colitis and the impossibility to 
further treat with AZA as a steroid-sparing 
agent, we decided to start infliximab on the 
ninth day of hospitalization both for induc-
tion and maintenance therapy. According 
to a telephone follow-up 1 year later, there 
were no recurrences of his symptoms, and 
his colitis was well controlled by therapy 
with infliximab and mesalazine.
 A very recent review of the literature up 
to the 30th of May 2014 identified 16 re-
ported cases of AZA-induced SS ( table 2 ) 
 [4–8, 10–17] . Analysis of these 16 reported 
cases shows an age distribution upon onset 
ranging from 9 to 89 years, an association 
of AZA-induced SS with IBD in 13 of 16 
cases (81%), and an onset within the first 
month of AZA therapy (with an average 
time to onset of 33 days, range 7–330) in 15 
of 16 patients (94%) ( table 2 ). In the seven 
case reports in which the thiopurine meth-
yltransferase (TPMT) levels were indicat-
ed, no deficiency in TPMT existed, making 
a defect in AZA methylation and metab-
olism unlikely, and the latter an unlikely 
cause of the observed neutrophilic derma-
tosis. Rechallenge with AZA was tested in 
6 of the reported cases and was positive in 
bc
a
 Fig. 1. Florid cutaneous eruption of the upper torso, face and neck consisting of erythem-
atous papulopustular lesions 2–10 mm in diameter, many of them with a central depres-
sion and/or erosion ( a ,  c ), evolving over time to central crusting ( b ). 
 Fig. 2. Large aphthous lesions with a fibri-
nous base on the hard palate. 
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all of them, thus indicating direct causality 
of AZA in these cases of SS.
 The pathogenesis of SS is incompletely 
understood. The association with underly-
ing diseases and drugs suggests a hypersen-
sitivity reaction, and it has been suggested 
that a dysregulation of cytokine release in-
cluding IL-1, granulocyte-macrophage col-
ony-stimulating factor (GM-CSF), G-CSF 
and interferon-γ may be involved  [18, 19] . 
Based on reports linking IL-1β to diseases 
associated with neutrophilic infiltration of 
the skin, such as the rare genetic autoin-
flammatory syndrome associating pyogen-
ic arthritis, pyoderma gangrenosum and 
acne, named PAPA syndrome  [20] , and the 
cryopyrin-associated periodic syndromes 
(CAPS)  [21] , we analyzed IL-1β expression 
levels in the skin lesions of the reported pa-
tient. As shown in  figure 4 , mRNA levels 
for IL-1β in our patient’s skin biopsy as-
sessed by quantitative RT-PCR with cDNA 
primers for the housekeeping gene RPL27 
(forward 5 ′ -ATC GCC AAG AGA TCA 
AAG ATA A-3 ′ , reverse 5 ′ -TCT GAA 
GAC ATC CTT ATT GAC G-3 ′ ) and IL-1β 
(forward 5 ′ -CAC GAT GCA CCT GTA 
CGA TCA-3 ′ , reverse 5 ′ -GTT GCT CCA 
TAT CCT GTC CCT-3 ′ ) were over 250-
fold higher than those observed in normal 
skin, and this was associated with enhanced 
expression of the mature active form of IL-
1β in inflammatory cells – mainly neutro-
phils – of the dermal infiltrate as identified 
by immunohistochemistry.
 Discussion 
 Acute febrile neutrophilic dermatosis 
or SS is a prototypic neutrophilic dermato-
sis first described in 1964 by Dr. Robert 
Douglas Sweet  [1] . The characteristic clini-
cal manifestations of this disorder include 
acute eruption of tender, red or purple-red 
papules, nodules or plaques, occasionally 
associated with pustules, bullae or ulcers, 
and constant systemic symptoms (pyrexia, 
fatigue). Together with cutaneous manifes-
tation SS can nearly involve any organ sys-
tem. Inflammation in some of these organs 
can cause serious long-term quality of life 
impairment. The sight-threatening ocular 
manifestations merit particular mention 
 [22] . Cutaneous biopsies reveal an inflam-
matory infiltrate consisting mainly of ma-
ture neutrophils in the upper dermis.
 The pathogenesis of SS is unknown. 
The association of the disorder with infec-
tions, IBD, drugs, autoimmune diseases 
and malignancies, as well as the higher in-
cidence in women, suggest a hypersensitiv-
ity reaction  [23] . One current attractive hy-
pothesis regarding the pathogenesis of SS is 
a local or systemic dysregulation of cyto-
kine secretion. Among the potentially re-
sponsible cytokines are IL-1, IL-3, IL-6, IL-
8, G-CSF, GM-CSF and interferon-γ  [18] . 
Elevated serum levels of IL-1, IL-2 and 
interferon-γ, but not IL-4, suggest that the 
expression of Th1 cytokines may be in-
volved in the pathogenesis of this syn-
drome  [18] .
 SS does fulfill the current criteria for 
classification as an autoinflammatory dis-
ease  [24] . Autoinflammatory diseases are a 
relatively new category of diseases distinct 
from allergic and autoimmune diseases 
and characterized by seemingly unpro-
voked recurrent inflammation in the ab-
sence of evidence of circulating autoan-
tibodies or an antigen-specific T cell re-
sponse  [25] . Genetic mutations affecting 
proteins of the inflammasome complex or 
proteins that regulate the function of the 
inflammasome have been found in several 
of the autoinflammatory syndromes. In-
Table 1. Summary of laboratory investigation findings
Test Result Normal range
Hemoglobin, g/dl 9.1 13.4 – 17.0
White cell count, ×103/μl 22.4 3.0 – 9.6
Neutrophils, ×103/μl 20.16 1.4 – 8.0
Platelets, ×103/μl 602 143 – 400
Sodium, mmol/l 134 136 – 145
Potassium, mmol/l 3.9 3.3 – 4.5
Urea, mmol/l 6.6 2.14 – 7.14
Creatinine, μmol/l 94 62 – 106
Albumin, g/l 27 40 – 49
C-reactive protein, mg/l 193 <5
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 Fig. 3. Skin biopsy taken on the upper back showing marked superficial edema with florid 
neutrophilic infiltration of the whole dermal thickness. Hematoxylin and eosin, ×100. 
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 Fig. 4.  a Analysis of IL-1β mRNA levels by quantitative RT-PCR in the patient’s skin bi-
opsy and healthy control skin.  b Immunohistochemical stainings with an anti-IL-1β an-
tibody and with an appropriate isotype control antibody were performed on the patient’s 
skin biopsy and compared to anti-IL-1β antibody staining in healthy control skin. 
Co
lo
r v
er
si
on
 a
va
ila
bl
e 
on
lin
e
 Table 2.  Reported cases of AZA-induced SS
Case No. 
[ref.]
Age, years/
sex
Underlying disease Time of onset after
starting AZA
Recurrence with
rechallenge
TPMT level Concurrent
steroid use
1 [8] 9/F ulcerative colitis 10 days no rechallenge N yes
2 [4] 39/F Crohn’s disease 28 days yes N yes
3 [4] 33/M systemic lupus erythematosus 14 days no rechallenge N yes
4 [14] 46/M ulcerative colitis 14 days yes NR yes
5 [6] 49/M ulcerative colitis 11 months yes NR yes
6 [7] 32/M Crohn’s disease 7 days yes above ref. range yes
7 [7] 68/M myasthenia gravis 10 days no rechallenge above ref. range yes
8 [7] 42/M ulcerative colitis 14 days no rechallenge NR yes
9 [13] 89/F bullous pemphigoid 18 days no rechallenge N yes
10 [11] 45/M Crohn’s disease 14 days yes NR yes
11 [12] 55/M Crohn’s disease 7 days yes NR yes
12 [10] 53/M ulcerative colitis 7 days no rechallenge NR yes
13 [15] 50/M indeterminate colitis 14 days no rechallenge NR yes
14 [17] 75/M Crohn’s disease 14 days no rechallenge NR no
15 [5] 81/F Crohn’s disease 14 days no rechallenge NR yes
16 [16] 51/M Crohn’s disease 10 days no rechallenge N yes
 F = Female; M = male; N = normal; NR = not reported.
a
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flammasomes are a group of protein com-
plexes that recognize a diverse set of patho-
gen- and/or danger-associated inflamma-
tion-inducing stimuli and that control the 
production of important proinflammatory 
cytokines such as IL-1β and IL-18  [26] . 
Mutations in inflammasome components 
may result in overactivity of the inflamma-
some or failure to limit IL-1-mediated in-
flammation, as is the case in CAPS such as 
Muckle-Wells syndrome that are due to ac-
tivating mutations of the inflammasome 
component NLRP3. In a large number of 
autoinflammatory diseases, systemic corti-
costeroids have only modest effect. Biolog-
ic agents such as anakinra (Kineret ® ), a re-
combinant IL-1R antagonist, can result in 
a dramatic and consistent improvement in 
those syndromes where a clear link to IL-1 
has been shown  [27] . Likewise therapy with 
canakinumab, a human monoclonal anti-
body targeted at IL-1β, has been shown to 
induce rapid, durable and complete clinical 
responses in 97% of CAPS patients studied 
 [28] . Our data showing very high levels of 
IL-1β mRNA and protein in the skin le-
sions of our patient are supportive of the 
above notion that SS is an autoinflamma-
tory disease, and suggest that IL-1β may 
contribute to the neutrophilic infiltration 
of the skin and fever that characterize SS. 
According to the recently updated classi-
fication of autoinflammatory disease, our 
case is a type 1, complex/acquired autoin-
flammatory disease  [25] .
 Prednisone or prednisolone at an ini-
tial dose of 0.5–1.5 mg/kg body weight/
day, with gradual tapering over 2–4 weeks, 
represents the standard first-line treat-
ment for SS. In recurrent disease, therapy 
with colchicine, potassium iodide, dap-
sone, doxycycline, non-steroidal anti-in-
flammatory agents and cyclosporine has 
been described, with mixed results  [29] . A 
few case reports mention successful use of 
infliximab (5 mg/kg) on a compassionate 
use basis in refractory SS. Evidence for any 
of these therapeutic regimens is however 
limited as based on case reports and small 
case series. Recently very encouraging re-
sponses to Kineret have been reported in 
patients with refractory SS, further sug-
gesting that IL-1α or IL-1β play a signifi-
cant role in the pathophysiology of this 
disease  [30, 31] .
 One of the more frequently reported 
diseases associated with classical SS is IBD. 
Benton et al.  [32] described its association 
with ulcerative colitis for the first time in 
1985. Since then, a large number of case re-
ports have confirmed this association  [32–
46] . The association of SS with Crohn’s dis-
ease is less common, with fewer than 40 
cases described in the literature. SS associ-
ated with IBD tends to be more common in 
women (87%) and is usually associated 
with active disease  [47] . The presence of
extraintestinal symptoms, such as joint 
symptoms and other skin manifestations, 
is frequent in patients with IBD-associated 
SS  [48] . As mentioned earlier, SS may be 
also associated with medications  [2] , the 
administration of G-CSF being respon-
sible for the majority of drug-induced cas-
es of SS. Many patients with IBD are treat-
ed with AZA as a corticosteroid-sparing 
agent. When SS occurs in such patients, 
IBD is the first suspected cause of the syn-
drome, given the well-reported association 
 [10, 15] . However, in the last few years sev-
eral papers reporting a possible association 
between AZA and SS have been published 
( table 2 )  [4–8, 10–17] . Interestingly, two of 
the cases reporting AZA-associated SS had 
an underlying disease other than IBD, and 
rechallenge of patients with AZA repro-
duced SS lesions in all 6 cases rechallenged, 
both facts providing support for a poten-
tial role of AZA as a trigger/co-factor in 
certain cases of SS  [4, 7] .
 The AZA hypersensitivity syndrome, 
which typically occurs within the first 4 
weeks of initiation of AZA therapy  [9] and 
is characterized by systemic symptoms 
identical to those of SS (fever, leukocytosis, 
malaise, arthralgia), was considered to be 
the cause in many of these cases ( table 2 ). 
A review of the English language literature 
by Bidinger et al.  [4] showed that about 
50% of patients with a hypersensitivity re-
action to AZA had cutaneous manifesta-
tions. The majority thereof had biopsy or 
clinical features consistent with a neutro-
philic dermatosis. Interestingly, withdraw-
al of AZA and rechallenge with the drug 
indicated that at least in some of the above-
mentioned cases  [4, 6, 7, 11, 12, 14] , a direct 
association between AZA and SS existed. 
In another case, on the other hand, the 
AZA dose was increased and the rash even-
tually resolved  [41] . As the systemic mani-
festations described for AZA hypersensi-
tivity syndrome have all also been reported 
to occur with varying frequencies in SS, it 
is presumed that both denominations refer 
to variants of the same disease  [49, 50] .
 Our patient with SS developing 14 days 
after initiation of AZA therapy for active 
IBD meets all of the diagnostic criteria for 
drug-induced SS as presented by Walker 
and Cohen in 1996  [51] . Especially the lo-
calization and the clinical outcome argu-
ments against the presence of an AZA hy-
persensitivity syndrome. The latter tends 
to favor the lower extremities and most cas-
es resolve within 2–3 days after withdrawal 
of the medication and may not necessitate 
an increase in corticosteroid dose. In view 
of the impressive clinical presentation re-
sulting in permanent skin scarring, rechal-
lenge with AZA as a proof of causality was 
not performed. Full resolution of clinical 
symptoms occurred upon therapy with 
systemic steroids and infliximab. Our data 
showing involvement of IL-1β in SS, taken 
together with reports of successful therapy 
of SS with the IL-1 receptor antagonist 
anakinra, suggest that IL-1 plays a role in 
the pathogenesis of SS, and the latter ther-
apy may be optimal in steroid-refractory 
cases of SS. However, anakinra was not 
shown to be effective in IBD. For that rea-
son a different strategy was chosen in the 
patient discussed here.
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